215 related articles for article (PubMed ID: 28317392)
1. Pharmacotherapy of major depression in late life: what is the role of new agents?
Patel K; Abdool PS; Rajji TK; Mulsant BH
Expert Opin Pharmacother; 2017 Apr; 18(6):599-609. PubMed ID: 28317392
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G
J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738
[TBL] [Abstract][Full Text] [Related]
3. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Deardorff WJ; Grossberg GT
Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
[TBL] [Abstract][Full Text] [Related]
4. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2015 Feb; 69(2):151-5. PubMed ID: 25627335
[No Abstract] [Full Text] [Related]
5. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
Atsou K; Ereshefsky L; Brignone M; Danchenko N; Diamand F; Mucha L; Touya M; Becker R; François C
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):29-42. PubMed ID: 33307885
[No Abstract] [Full Text] [Related]
7. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling.
Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D
J Affect Disord; 2016 Jan; 190():357-361. PubMed ID: 26546771
[TBL] [Abstract][Full Text] [Related]
8. Levomilnacipran and Vortioxetine for Adults with Major Depressive Disorder.
Scarff JR
J S C Med Assoc; 2015 Dec-2016 Jan; 111(4):131-3. PubMed ID: 27141705
[No Abstract] [Full Text] [Related]
9. Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.
Roman MW; Wilkinson SM
Issues Ment Health Nurs; 2014 Dec; 35(12):972-4. PubMed ID: 25426751
[TBL] [Abstract][Full Text] [Related]
10. Advances in Pharmacotherapy of Late-Life Depression.
Beyer JL; Johnson KG
Curr Psychiatry Rep; 2018 Apr; 20(5):34. PubMed ID: 29627920
[TBL] [Abstract][Full Text] [Related]
11. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
Sahli ZT; Banerjee P; Tarazi FI
Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
[TBL] [Abstract][Full Text] [Related]
12. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
[TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for major depressive disorder.
Connolly KR; Thase ME
Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
[TBL] [Abstract][Full Text] [Related]
14. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Li G; Wang X; Ma D
Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
Meeker AS; Herink MC; Haxby DG; Hartung DM
Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.
Dubovsky SL
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):759-66. PubMed ID: 24684240
[TBL] [Abstract][Full Text] [Related]
17. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients?
Danielak D
Expert Opin Pharmacother; 2021 Jun; 22(9):1167-1177. PubMed ID: 33650935
[No Abstract] [Full Text] [Related]
18. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
19. Vilazodone: a new treatment option for major depressive disorder.
Owen RT
Drugs Today (Barc); 2011 Jul; 47(7):531-7. PubMed ID: 22013560
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]